MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Vivani Medical

Uždarymo kaina

1 -4.76

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.99

Max

1.03

Pagrindiniai rodikliai

By Trading Economics

Darbuotojai

36

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+471.43% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-09

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

61M

Ankstesnė atidarymo kaina

5.76

Ankstesnė uždarymo kaina

1

Vivani Medical Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2024-06-13 15:28; UTC

Pagrindinės rinkos jėgos

Vivani Medical Shares Up, FDA Cleared New Drug Application to Start Diabetes Trial

Akcijų palyginimas

Kainos pokytis

Vivani Medical Prognozė

Kainos tikslas

By TipRanks

471.43% į viršų

12 mėnesių prognozė

Vidutinis 6 USD  471.43%

Aukščiausias 8 USD

Žemiausias 4 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Vivani Medical kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

2

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

$

Apie bendrovę Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.